Promoter holding
64.27%
GP
Goldline Pharmaceutical Limited - Due diligence report
A 360° intelligence report on Goldline Pharmaceutical Limited: trust score, financial health, credit view, compliance, directors, growth and…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Goldline Pharmaceutical Limited — 360° Intelligence Report
Generated from MCA filings & public records77/100
Trust Score
Low Risk
Goldline Pharmaceutical Limited is assessed as Low Risk with a Trust Score of 77/100. Goldline Pharmaceutical Limited is an active public limited indian non-government company incorporated in 2004, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.
Report generated on 14 Aug 2026 from the latest processed filings. Goldline Pharmaceutical Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
77/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
63/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
75/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
65/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
55/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 65/100 Moderate
- Open charges exceed net worth - secured lenders rank ahead.
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (B+).
Charges position: 3 open (8.54 cr) · 2 satisfied (3.53 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Bank Of India | 3 | 48.0 cr |
| State Bank Of India | 1 | 48.0 cr |
| Others | 1 | 48.0 cr |
Compliance Score: 63/100 Moderate
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Flagged by authority: EPFO.
- Litigation present in 1 court forum(s).
- 1 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| SWAPAN KHANDELWAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AMOL LAXMIKANT MUJUMDAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MEHUL HARI RANADE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RUCHI SANKET MODI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PRASHANT SHRIKRISHNA KARKARE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Renuka Saurabh Borole | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Shraddha Kiran Kulkarni | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PRASHANT VITHALRAO RAHATE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AVINASH PANDURANG AMBULKAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Dipti Sharad Bhusari | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 10 directors on the board.
- No disqualified or deactivated DINs.
- 2 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
11 allotment(s) · 2 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
Key managerial personnel: SWAPAN KHANDELWAL (Whole-time director) · AMOL LAXMIKANT MUJUMDAR (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 55 · Distress 75
Growth signals & trust indicators
Profit expanded 38% year-on-year.
Net margin improved to 1.42.
Operating for 22+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
3 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence71/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment68/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 3 open charge(s) of 8.54 cr already registered.
- Compliance gaps should be priced into terms.
Investor view68/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2025
Last AGM held
Annual general meeting
29 Sep 2025
Director ceased
Shraddha Kiran Kulkarni
31 Mar 2025
Latest balance sheet
Filed with ROC
17 Jan 2025
Director appointed
Dipti Sharad Bhusari (Cfo)
12 Dec 2024
Charge created
Others - 42.10 Lakh
05 Dec 2024
Charge satisfied
Bank Of India
05 Nov 2024
Director appointed
RUCHI SANKET MODI (Company Secretary)
17 Oct 2024
Director appointed
Shraddha Kiran Kulkarni (Director)
30 Sep 2024
Director appointed
MEHUL HARI RANADE (Director)
Director appointed
Renuka Saurabh Borole (Director)
Director appointed
PRASHANT VITHALRAO RAHATE (Director)
09 Mar 2024
Director ceased
DHANRAJ KARBHARI CHAVAN
02 May 2022
Charge created
Bank Of India - 46.00 Lakh
10 Nov 2021
Director ceased
SWAPAN KHANDELWAL
20 Oct 2018
Securities allotted
5000 Preference Shares - 5.00 Lakh raised
10
Key Observations
Auto-generated from the data aboveRevenue declined 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Debt-to-equity stands at 61% - leverage worth monitoring.
Net worth is positive.
10 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of B+ from Crisil.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 11 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Puritz Chem Private Limited | U24304DL2018PTC336473 | New Delhi, Delhi, India |
| Impact Healthcare Private Limited | U85191DL2007PTC166197 | New Delhi, Delhi, India |
| Sapient Laboratories Private Limited | U24231DL2003PTC118652 | New Delhi, Delhi, India |
| Steuler Industrial Solution (India) Private Limited | U26999GJ2019PTC106563 | Bharuch, Gujarat, India |
| Msrm Organics Private Limited | U01400TG2017PTC116393 | Shaikpet, Telangana, India |
| Sarvodaya Solvents Private Limited | U24100TG2011PTC076160 | Hyderabad, Telangana, India |
| Macson Color Chem Private Limited | U52100GJ2011PTC064732 | Surat, Gujarat, India |
| Hiya Healthcare Private Limited | U51909MH2020PTC339697 | Bhiwandi, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Goldline Pharmaceutical Limited before audits and certifications: compliance score 63/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Goldline Pharmaceutical Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 65/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 55/100, margin trends, ownership structure and peer set for Goldline Pharmaceutical Limited - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 77/100, distress signals and MSME payment-delay disclosures - know whether Goldline Pharmaceutical Limited pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Goldline Pharmaceutical Limited - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Goldline Pharmaceutical Limited an active company?
Goldline Pharmaceutical Limited has MCA status “Active” with a compliance score of 63/100 (Moderate).
Is Goldline Pharmaceutical Limited financially healthy?
Goldline Pharmaceutical Limited has a Financial Health Score of 75/100 (Low Risk) based on its filed financial statements.
Should I do business with Goldline Pharmaceutical Limited?
Its overall Trust Score is 77/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Goldline Pharmaceutical Limited?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 10 active director(s) are on record.
Does Goldline Pharmaceutical Limited have loans or charges against its assets?
3 open charge(s) are registered against its assets, and 2 earlier charge(s) stand satisfied.
Is Goldline Pharmaceutical Limited up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 63/100 (Moderate).
Is it risky to lend to Goldline Pharmaceutical Limited?
Its Credit Risk Score is 65/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
